研报掘金丨华福证券:维持昆药集团“买入”评级,看好华润赋能公司

格隆汇
20 Feb

华福证券研报指出,昆药集团(600422.SH)24Q4单季预计实现归母扣非1.47亿元,23Q4单季度归母扣非为0.25亿元,实现快速增长。2024年系公司公司加入华润大家庭、与华润三九稳步推进融合重塑的第二年;圣火完成并表标志着公司已解决核心产品血塞通软胶囊“络泰”与华润圣火“理洫王”同业竞争问题,全国仅有的两张血软批文合为一家,未来公司有望进一步完善三七产业链优势布局,提升公司在心脑血管疾病...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10